Prognostic Significance of Ultralow (UL) Prostate-Specific Antigen (PSA) in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Single Institution and Tertiary Cancer Center Experience.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
29 patients (40.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
However, we identified patients achieving UL PSA levels, who experienced radiographic progression. Our finding suggests that even among "best" PSA responders, some might develop resistant clones that manifest via imaging progression without PSA rise.
Prostate-specific antigen (PSA) concentration is considered an important prognostic marker, with rapid and large reductions associated with a favorable outcome and prolonged survival.
APA
Suton P, Gregov V (2025). Prognostic Significance of Ultralow (UL) Prostate-Specific Antigen (PSA) in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Single Institution and Tertiary Cancer Center Experience.. Medicina (Kaunas, Lithuania), 61(12). https://doi.org/10.3390/medicina61122110
MLA
Suton P, et al.. "Prognostic Significance of Ultralow (UL) Prostate-Specific Antigen (PSA) in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Single Institution and Tertiary Cancer Center Experience.." Medicina (Kaunas, Lithuania), vol. 61, no. 12, 2025.
PMID
41470112 ↗
Abstract 한글 요약
Prostate-specific antigen (PSA) concentration is considered an important prognostic marker, with rapid and large reductions associated with a favorable outcome and prolonged survival. We conducted a single institution and tertiary cancer center retrospective analysis of metastatic hormone-sensitive prostate cancer (mHSPC) patients undergoing active treatment at Division of Oncology and Radiotherapy, University Hospital Dubrava, between December 2022 and August 2025. This study aimed to assess the association between the PSA levels and survival in mHSPC patients undergoing active treatment. A total of 42 (59.2%) in our cohort achieved UL PSA levels, while 29 patients (40.8%) had PSA levels > 0.2 ng/mL. Cox regression analysis identified age > 71 years at the diagnosis of mHSPC and UL PSA levels as statistically significant factors associated with favorable outcome. Our real-world data demonstrated that UL PSA is a favorable prognostic factor associated with prolonged survival and improved prognosis. However, we identified patients achieving UL PSA levels, who experienced radiographic progression. Our finding suggests that even among "best" PSA responders, some might develop resistant clones that manifest via imaging progression without PSA rise.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.